## HIGHLIGHTS

### 2387 Selected Articles from This Issue

## COMMENTARY

### 2389 Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success
Erika A. Waters, Jennifer M. Taber, Amy McQueen, Ashley J. Houston, Jamie L. Studts, and Laura D. Scherer

### 2454 Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review
Michael A. Liss, Robin J. Leach, Martin G. Sanda, and Oliver J. Semmes

## CEBP FOCUS

### 2396 The National Cancer Institute Early Detection Research Network: Two Decades of Progress
Robert C. Bast Jr and Sudhir Srivastava

### 2401 The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers
Sudhir Srivastava and Paul D. Wagner

### 2411 Biomarkers for Lung Cancer Screening and Detection
Edwin J. Ostrin, David Sidransky, Avrum Spira, and Samir M. Hanash

### 2416 Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation
Maria Farooq and James G. Herman

### 2423 Lung Cancer and Immunity Markers
Raymond J. Lim, Bin Liu, Kostyantyn Krysan, and Steven M. Dubinett

### 2431 Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation
Robert S. Bresalier, William M. Grady, Sanford D. Markowitz, Hans Jørgen Nielsen, Surinder K. Batra, and Paul D. Lampe

### 2495 Biomarkers for the Early Detection of Hepatocellular Carcinoma
Neelam S. Mehta, Anand S. Mehta, Amit G. Singal, Timothy Block, Jorge A. Marrero, and Anna S. Lok

### 2504 Biomarkers and Strategies for Early Detection of Ovarian Cancer
Robert C. Bast Jr, Zhen Lu, Chae Young Han, Karen H. Lu, Karen S. Anderson, Charles W. Drescher, and Steven J. Skates

### 2513 Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN
Ying Liu, Sukhwinder Kaur, Ying Huang, Johannes F. Fahrmann, Jo Ann Rinaudo, Samir M. Hanash, Surinder K. Batra, Aatur D. Singhi, Randall E. Brand, Anirban Maitra, and Brian B. Haab
TABLE OF CONTENTS

2524  Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network  
Harvey I. Pass, Marjan Alimi, Michele Carbone, Haining Yang, and Chandra M. Goparaju

2541  The Potential of Circular RNAs as Cancer Biomarkers  
Jason R. Brown and Arul M. Chinnaian

2556  Radiomics Improves Cancer Screening and Early Detection  
Robert J. Gillies and Matthew B. Schabath

2568  Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA  
Annie H. Ren, Clare A. Fiala, Eleftherios P. Diamandis, and Vathany Kulasingam

2575  Adding Rigor to Biomarker Evaluations—EDRN Experience  
Ziding Feng and Margaret S. Pepe

RESEARCH ARTICLES

Jessica Y. Islam, Marlene Camacho-Rivera, and Denise C. Vidot

2591  Premature Years of Life Lost Due to Cancer in the United States in 2017  
Minkyo Song, Allan Hildesheim, and Meredith S. Shiels

2599  Strategizing Screening for Melanoma in an Era of Novel Treatments: A Model-Based Approach  
Kemal Caglar Goğebakan, Elizabeth G. Berry, Alan C. Geller, Kemal Sonmez, Sancy A. Leachman, and Ruth Etzioni

2608  Daily Physical Activity and Symptom Reporting in Breast Cancer Patients Undergoing Chemotherapy: An Intensive Longitudinal Examination  

2617  Associations of Leisure-Time Physical Activity and Television Viewing with Life Expectancy Cancer-Free at Age 50: The ARIC Study  
Carmen C. Cuthbertson, Hazel B. Nichols, Xianming Tan, Anna Kucharska-Newton, Gerardo Heiss, Corinne E. Joshu, Elizabeth A. Platz, and Kelly R. Evenson

2626  Community-Acquired Escherichia coli Bacteremia after Age 50 and Subsequent Incidence of a Cancer Diagnosis: A Danish Population-Based Cohort Study  
Kirstine K. Søgaard, Katalin Veres, Christina M.J.E. Vandenbroucke-Grauls, Jan P. Vandenbroucke, Henrik T. Serensen, and Henrik C. Schønheyder

2633  Low Levels of Alcohol Consumption and Risk of Intestinal Metaplasia: A Cohort Study  
Kyungeun Kim, Yoonsoo Chang, Jiin Ahn, Hyo-Joon Yang, and Seungho Ryu

2642  Methylated DNA Markers of Esophageal Squamous Cancer and Dysphagia: An International Study  

2651  Extended HPV Genotyping to Compare HPV Type Distribution in Self- and Provider-Collected Samples for Cervical Cancer Screening  

2659  Association between Receipt of Guideline-Concordant Lung Cancer Treatment and Individual- and Area-Level Factors: A Spatio-Temporal Analysis  
Win Wah, Rob G. Stirling, Susannah Ahern, and Arul Earnest

2662  HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study  
Christina Carlander, Camilla Ladheden, Carina Eklund, Sara Nordqvist Kleppe, Mensur Dzabic, Philippe Wagner, Aylin Yilmaz, Kristina Elfgren, Anders Sönnerborg, Pär Sparén, and Joakim Dillner

2669  HPV Types in Cervical Precancer by HPV Status and Birth Region: A Population-Based Register Study  
Christina Carlander, Camilla Ladheden, Carina Eklund, Sara Nordqvist Kleppe, Mensur Dzabic, Philippe Wagner, Aylin Yilmaz, Kristina Elfgren, Anders Sönnerborg, Pär Sparén, and Joakim Dillner

2680  A Large Cohort Study of Body Mass Index and Pancreatic Cancer by Smoking Status  
Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Alpa V. Patel, W. Dana Flanders, and Susan M. Gapstur

2686  Replication and Genetic Risk Score Analysis for Pancreatic Cancer in a Diverse Multiethnic Population  
David Bogumil, David V. Conti, Xin Sheng, Lucy Xia, Xiao-ou Shu, Stephen J. Pandol, William J. Blot, Wei Zheng, Loic Le Marchand, Christopher A. Haiman, and Veronica Wendy Setiawan
Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp
Dong Hoon Lee, Chao Cao, Xiaoyu Zong, Xuehong Zhang, Kelli O’Connell, Mingyang Song, Kana Wu, Mengmeng Du, Yin Cao, Edward L. Giovannucci, and Elizabeth D. Kantor

Evaluation of Circulating Tumor DNA for Methylated BCA1T and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC)
Benjamin L. Musher, Joshua E. Melson, Gianni Amato, David Chan, Marisa Hill, Iftekhar Khan, James Orsini Jr, Susanne K. Pedersen, Bruce Robb, Joel Saltzman, Jennifer Silinsky, Snigdha Gaur, Melissa K. Tuck, Lawrence C. LaPointe, and Graeme P. Young

Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Natalia Kunst, Fernando Alarid-Escudero, Eline Aas, Veerle M.H. Coupie, Deborah Schrag, and Karen M. Kuntz

Genetic Variants in the Regulatory T cell–Related Pathway and Colorectal Cancer Prognosis

Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk

The Role of Dissemination and Implementation Research in Global Tobacco Control: A Report from the American Society of Preventive Oncology
Ramzi G. Salloum, Mark Parascandola, Jennifer H. LeLaurin, and Donna Shelley
ABOUT THE COVER

The cover image is adapted from Figure 3 in the article, "Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review," by Liss and colleagues. The figure shows an MRI-Ultrasound Fusion-guided technique for targeted prostate biopsy. Prostate cancer remains the most common non-skin cancer and second leading cause of death among men in the United States. Although progress has been made in diagnosis and risk assessment, many clinical questions remain regarding early identification of prostate cancer and management. The early detection of aggressive disease continues to provide high curative rates if diagnosed in a localized state. Unfortunately, prostate cancer displays significant heterogeneity within the prostate organ and between individual patients, making detection and treatment strategies complex. Although prostate cancer is common among men, the majority will not die from prostate cancer, introducing the issue of overtreatment as a major concern in clinical management of the disease. The focus of the future is to identify those at highest risk for aggressive prostate cancer and to develop prevention and screening strategies, as well as discerning the difference in malignant potential of diagnosed tumors. The Prostate Cancer Research Group of the National Cancer Institute’s Early Detection Research Network (EDRN) has contributed to the progress in addressing these concerns. The strong focus on biomarker application optimizes the development of biomarkers with clinical utility as well as the early adoption of disruptive technologies, such as MRI imaging, into biomarker development workflows. Likewise, efforts to validate findings from laboratories outside of the EDRN, such as polygenic risk scores and capture of in-depth data from clinical cohorts provide unique resources to the biomarker community. For more information, see the article beginning on page 2454.